NCT04254354

Brief Summary

The aim of this study is to investigate transgender men and non-binary persons before and during testosterone treatment. The study will focus on:

  • Cardiovascular status
  • Muscle strenght and power
  • Aggression and quality of life
  • Cardiac and respiratory function

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
215mo left

Started Mar 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress26%
Mar 2020Jan 2044

First Submitted

Initial submission to the registry

January 21, 2020

Completed
15 days until next milestone

First Posted

Study publicly available on registry

February 5, 2020

Completed
27 days until next milestone

Study Start

First participant enrolled

March 3, 2020

Completed
23.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2044

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2044

Last Updated

August 13, 2025

Status Verified

August 1, 2025

Enrollment Period

23.8 years

First QC Date

January 21, 2020

Last Update Submit

August 8, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Effect of testosterone on devellopment of plaques in the heart

    Estimated directly by CCTA, at start, (1 year for early included participants) 5 and 10 years

    10 years

Secondary Outcomes (12)

  • Calcium score

    10 years

  • Change in muscle strength and power

    10 years

  • Effect of transgender treatment on quality of life

    10 years

  • Effect of transgender treatment on aggression

    10 years

  • Changes in maximal oxygen consumption during transgender treatment

    10 years

  • +7 more secondary outcomes

Study Arms (1)

transgender men

no intervention

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Persons assigned female at birth (+18 years) that either use or want to use testosterone with the purpose of undergoing gender transformation. -

You may qualify if:

  • Transgender men

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Odense University Hospital

Odense, 5000, Denmark

RECRUITING

Related Publications (1)

  • Lehmann Christensen L, Glintborg D, Taulbjerg Kristensen T, Diederichsen A, T'Sjoen G, Frystyk J, Skovsager Andersen M. Masculinising testosterone treatment and effects on preclinical cardiovascular disease, muscle strength and power, aggression, physical fitness and respiratory function in transgender men: protocol for a 10-year, prospective, observational cohort study in Denmark at the Body Identity Clinic (BIC). BMJ Open. 2020 Dec 29;10(12):e045714. doi: 10.1136/bmjopen-2020-045714.

Biospecimen

Retention: SAMPLES WITH DNA

blood, urine, hair

MeSH Terms

Conditions

Transsexualism

Condition Hierarchy (Ancestors)

SexualitySexual BehaviorBehavior

Study Officials

  • Marianne Andersen

    Odense University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

marianne andersen, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 21, 2020

First Posted

February 5, 2020

Study Start

March 3, 2020

Primary Completion (Estimated)

January 1, 2044

Study Completion (Estimated)

January 1, 2044

Last Updated

August 13, 2025

Record last verified: 2025-08

Locations